Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

reddy, dr reddy's
Premium

The company launched seven products in the quarter and the launch momentum is expected to remain strong in the second half of the financial year

Ram Prasad Sahu Mumbai
Pharma major Dr Reddy’s Laboratories (DRL) posted better-than-expected September quarter results, riding on sales of the generic version of cancer drug, Revlimid in the US market. The launch of the limited competition product, production-linked incentives and product mix resulted in the company exceeding street estimates for operating and net profit by 40-50 per cent.

Tushar Manudhane and Sumit Gupta of Motilal Oswal Research had factored in sales of $30 million for Revlimid given that it was launched in September. With the North American sales at $344 million (44 per cent of overall sales) in the quarter as compared to $230

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 31 2022 | 6:26 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com